Overview
Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria (also known as SUCLA2-related mitochondrial DNA depletion syndrome) is a rare inherited metabolic disorder caused by mutations in the SUCLA2 gene, which encodes the beta subunit of succinyl-CoA ligase (succinate-CoA ligase, ADP-forming). This enzyme plays a critical role in the citric acid cycle and in maintaining mitochondrial DNA (mtDNA) copy number. Deficiency leads to progressive depletion of mtDNA in affected tissues, impairing mitochondrial energy production. The condition primarily affects the brain and skeletal muscles (encephalomyopathy), and is characteristically associated with elevated methylmalonic acid in the urine (methylmalonic aciduria), which serves as a biochemical hallmark distinguishing it from other mtDNA depletion syndromes. Clinical features typically present in infancy and include hypotonia (low muscle tone), progressive muscle weakness, psychomotor delay or regression, failure to thrive, feeding difficulties, and sensorineural hearing loss. Many patients develop dystonia, seizures, and progressive encephalopathy. Lactic acidosis is commonly observed in blood and cerebrospinal fluid. Additional features may include mild hepatic involvement and growth retardation. The disease follows a progressive course, and affected individuals often experience significant neurological deterioration over time. There is currently no cure for this condition. Treatment is supportive and symptomatic, focusing on nutritional support, management of seizures with anticonvulsant medications, physical therapy, and hearing aids or cochlear implants for hearing loss. Avoidance of valproic acid is generally recommended due to its potential to worsen mitochondrial dysfunction. Supplementation with cofactors such as coenzyme Q10 and riboflavin has been tried in some patients, though evidence of efficacy remains limited. Genetic counseling is recommended for affected families.
Also known as:
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
No FDA-approved treatments are currently listed for Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria.
Community
No community posts yet. Be the first to share your experience with Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria.
Start the conversation →Latest news about Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria
No recent news articles for Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria
What is Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria?
Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria (also known as SUCLA2-related mitochondrial DNA depletion syndrome) is a rare inherited metabolic disorder caused by mutations in the SUCLA2 gene, which encodes the beta subunit of succinyl-CoA ligase (succinate-CoA ligase, ADP-forming). This enzyme plays a critical role in the citric acid cycle and in maintaining mitochondrial DNA (mtDNA) copy number. Deficiency leads to progressive depletion of mtDNA in affected tissues, impairing mitochondrial energy production. The condition primarily affects the brai
How is Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria inherited?
Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria typically begin?
Typical onset of Mitochondrial DNA depletion syndrome, encephalomyopathic form with methylmalonic aciduria is infantile. Age of onset can vary across affected individuals.